Implementation of tuberculosis preventive therapy with INH-Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study.
3HP
TB elimination
TB infection
TB preventive therapy
end-TB
latent TB
tuberculosis
Journal
Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
5
12
2023
pubmed:
21
10
2023
entrez:
21
10
2023
Statut:
ppublish
Résumé
The primary objective of this study was to ascertain the acceptance, initiation, implementation and treatment completion rates of tuberculosis (TB) preventive therapy (TPT) using 3HP (INH-Rifapentine) among household contacts of microbiologically confirmed drug sensitive TB cases on anti-tubercular treatment under programmatic real-world settings. The secondary objectives were to estimate the prevalence and predictors of latent TB infection (LTBI) in household contacts of the index TB cases. We also ascertained the safety profile of the 3HP TPT regimen in the household contacts. This prospective observational study was conducted at 10 TB chest clinics in Delhi, India during 2022-2023. Household contacts aged 14 and older who tested positive for TB infection on a Tuberculin Skin test were initiated on the 3HP regimen. Logistic regression was performed by including statistically significant independent variables in multiple prediction models. p < 0.05 was considered statistically significant. STATA, version 15.1, was used to compute all analyses. A total of 1067 (84.68%) eligible contacts of microbiologically confirmed, drug sensitive TB cases underwent screening with tuberculin skin test (TST), 614 (95.6%) LTBI positive contacts accepted the initiation of TPT, and 564 (91.8%) of those initiated on TPT completed the treatment. The major reason for refusal of screening was the lack of perception of risk of TB disease due to asymptomatic status. The prevalence of LTBI positivity through TST was 61.5% (95% CI, 58.5%, 64.4%). Adverse events were reported by 195 (31.8%) contacts initiated on 3HP of which 20 participants discontinued TPT. None of the sociodemographic factors showed a significant association with LTBI positivity (except age) or TPT completion rates. LTBI management with 3HP is feasible among adolescent and adult household contacts in India with high rates of adherence from initiation until treatment completion. The maximum attrition of participants occurred at the time of screening for LTBI using TST.
Substances chimiques
rifapentine
XJM390A33U
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
890-900Subventions
Organisme : NTEP, Government of NCT
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
WHO. The end TB strategy. https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy
WHO. Global TB report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-1-tb-incidence
Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
Awad SF, Critchley JA, Abu-Raddad LJ. Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: modelling based predictions. Epidemics. 2019;30:100381. https://doi.org/10.1016/j.epidem.2019.10038
Sharma N, Basu S, Chopra KK. Achieving TB elimination in India: the role of latent TB management. Indian J Tuberc. 2019 Jan;66(1):30-33. https://doi.org/10.1016/j.ijtb.2018.10.006
South-East Asia regional action plan on programmatic management of latent tuberculosis infection. New Delhi: World Health Organization, Regional Office for South-East Asia; 2018.
Auguste PE, Mistry H, McCarthy ND, Sutcliffe PA, Clarke AE. Cost-effectiveness of testing for latent tuberculosis infection in people with HIV. AIDS. 2022;36(1):1-9. https://doi.org/10.1097/QAD.0000000000003060
Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis. 2017;56:68-76. https://doi.org/10.1016/j.ijid.2016.11.006
Shah R, Khakhkhar T, Modi B. Efficacy and safety of different drug regimens for tuberculosis preventive treatment: a systematic review and meta-analysis. Cureus. 2023;15(4):e38182. https://doi.org/10.7759/cureus.38182
Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-Rifapentine regimen to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67(25):723-726. https://doi.org/10.15585/mmwr.mm6725a5
Tseng SY, Huang YS, Chang TE, Perng CL, Huang YH. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: a systematic review and meta-analysis. J Chin Med Assoc. 2021 Nov 1;84(11):993-1000. https://doi.org/10.1097/JCMA.0000000000000605
Government of India. India. TB report 2022. Available from: https://tbcindia.gov.in/WriteReadData/IndiaTBReport2022/TBAnnaulReport2022.pdf
Chauhan A, Parmar M, Dash GC, Solanki H, Chauhan S, Sharma J, et al. The prevalence of tuberculosis infection in India: a systematic review and meta-analysis. Indian J Med Res. 2023;157(2&3):135-151. https://doi.org/10.4103/ijmr.ijmr_382_23
Government of India. RNTCP. National strategic plan for tuberculosis elimination. 2017.
Reichler MR, Khan A, Sterling TR, Zhao H, Moran J, McAuley J, et al. Tuberculosis epidemiologic studies consortium task order 2 team. Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis. J Infect Dis. 2018;218(6):1000-1008. https://doi.org/10.1093/infdis/jiy265
National TB Elimination Programme. Central TB Division. Guidelines for Programmatic Management of Tuberculusosis Preventive Treatment in India 2021. Available from: https://tbcindia.gov.in/WriteReadData/l892s/Guidelines%20for%20Programmatic%20Management%20of%20Tuberculosis%20Preventive%20Treatment%20in%20India.pdf
Jaswal M, Farooq S, Madhani F, Noorani S, Salahuddin N, Amanullah F, et al. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):741-746. https://doi.org/10.5588/ijtld.21.0676
Sharma N, Basu S, Khanna A, Sharma P, Chandra S. The intention to receive tuberculosis preventive therapy in adult household contacts of pulmonary TB patients in Delhi. India J Infect Dev Ctries. 2022 Feb 28;16(2):298-304. https://doi.org/10.3855/jidc.14910
Nayak S, Acharjya B. Mantoux test and its interpretation. Indian. Dermatol Online J. 2012;3(1):2e6.
Yuen CM, Millones AK, Contreras CC, Lecca L, Becerra MC, Keshavjee S. Tuberculosis household accompaniment to improve the contact management cascade: a prospective cohort study. PLoS One. 2019;14(5):e0217104.
Bruxvoort KJ, Skarbinski J, Fischer H, Li Z, Eaton A, Qian L, et al. Latent tuberculosis infection treatment practices in two large integrated health Systems in California, 2009-2018. Open Forum Infect Dis. 2023;10(5):ofad219. https://doi.org/10.1093/ofid/ofad219
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20. https://doi.org/10.1128/CMR.00034-13
Krishnamoorthy Y, Ezhumalai K, Murali S, Rajaa S, Jose M, Sathishkumar A, et al. Prevalence and risk factors associated with latent tuberculosis infection among household contacts of smear positive pulmonary tuberculosis patients in South India. Tropical Med Int Health. 2021;26(12):1645-1651. https://doi.org/10.1111/tmi.13693
Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265. https://doi.org/10.1186/s12879-017-2377-
Rosenstock IM. The health belief model and preventive health behavior. In: Becker MH, editor. The health belief model and personal health Behmior. Slack, Thorofare: NJ; 1974. p. 42-50.